Table 2.

Clinical pathological parameters and expression of PinX1 for prognosis of NSCLC patients by univariate survival analysis (Long-rank test)

Variable	Learning cohort				Validation cohort
	Cases	Mean survival (months)	Media survival (months)	P-value*	Cases	Mean survival (months)	Media survival (months)	P-value*
Age(years)
<56a	42	27.6	25	0.199	22	26.3	21	0.899
≥56a	51	31.8	29		29	25.6	22
Gender
Male	61	29.4	27	0.996	35	24.2	19	0.385
Female	32	29.7	26		16	29.6	22
Smoking Condition
Smoker	42	22.5	18	0.000	20	20.1	17	0.042
Nonsmoker	51	35.4	33		31	29.7	27
WHO grade
G1	28	28.1	21	0.942	16	17.5	14	0.012
G2	37	30.3	27		20	26.4	22
G3	28	29.8	32		15	34.2	29
Histological Type
Squamous cell carcinoma	37	26.5	21	0.293	22	21.3	18	0.252
Adenocarcinoma	46	29.8	27		23	28.2	24
Others	10	36.5	32		6	35.2	27
T stage
T1-T2	38	39.1	37	0.000	18	31.6	31	0.009
T3-T4	55	22.4	16		33	23.3	19
N stage
N0	26	43.4	49	0.000	16	35.6	27	0.011
N1-N3	67	24.1	21		35	21.4	18
M stage
M0	66	35.6	34	0.000	35	30	25	0.004
M1	27	15	12		16	17	15
TNM stage
I-II	25	38.9	38	0.003	14	36.5	27	0.008
III-IV	68	26	24		37	21.8	18
PinX1 expression
Negative	56	24.8	21	0.008	27	19.4	18	0.005
Positive	37	36.2	34		24	32.6	28

*Long-rank test ^aMean age; T tumor, N node, M metastases